How long does it stay?
Determine how long your therapeutic or drug delivery system remains at the target site, providing quantitative evidence of residence time and biological permanence.
How long does your drug remain where it matters most?
Residence time at the target site is often as important as initial biodistribution for therapeutic success.
The method
BIOPERM quantifies how long a therapeutic or delivery system remains at its intended site of action. Using longitudinal in vivo quantitative imaging, a labeled therapeutic or delivery system is tracked throughout its expected residence window to measure target-site retention and washout. TheraPET4D® analyzes these data to derive residence time and clearance kinetics, providing a quantitative assessment of biopermanence.
By directly comparing formulations or delivery systems, BIOPERM generates the quantitative evidence needed to verify prolonged target-site retention and demonstrate improved therapeutic exposure.
The answers
How long does your drug remain at the target?
Residence time: Quantitative measurement of therapeutic retention at the tissue of interest.
Does your delivery strategy improve retention?
Formulation comparison: Direct comparison between formulations, drug delivery systems or dosing strategies.
How is the drug cleared over time?
Clearance & blood kinetics: Quantitative assessment of washout dynamics and systemic circulation.
Preclinical Models & Species
We offer access to a broad range of mouse and rat models, including healthy animals, orthotopic and subcutaneous tumor models, inflammation models, and selected transgenic models of neurodegenerative disease. The choice of animal strain and disease model is tailored to the specific objectives of each study.
Administration routes
We have extensive experience with a wide range of administration routes, including intravitreal, intra-articular and intracerebral delivery (via stereotaxic surgery). We also routinely perform systemic and conventional administrations such as subcutaneous and intramuscular injections. The administration route can be tailored to meet the specific requirements of your study.
Tracers
Your biologic or delivery system is labeled with the optimal positron-emitting isotope for its expected pharmacokinetic profile, ensuring high-quality PET imaging throughout its circulation. Labeling chemistry is carefully optimized to preserve the biological integrity, target binding, drug release characteristics (where applicable) and pharmacokinetic behavior of the therapeutic or delivery system.
Associated equipment
Can our delivery system increase the residence time of a peptide after intra-articular injection?
A company developing an intra-articular delivery system needed to demonstrate that its strategy prolonged peptide retention within the joint, thereby increasing local therapeutic exposure and providing quantitative evidence to support further development.
Study design
- 01
Peptide labeling and validation
- Conjugation and labeling of the peptide.
- Verification of preserved biological activity and target binding.
- 02
Delivery system formulation
- Encapsulation of the labeled peptide into the delivery system.
- 03
Longitudinal in vivo PET imaging and terminal ex vivo analysis (240 h)
- Intra-articular administration of the free labeled peptide and of the peptide loaded in the delivery system.
- PET/MRI imaging at 24, 48, 72, 168 and 240 hours post-injection.
- Organ collection and tissue radioactivity measurements.
- 04
TheraPET4D® quantitative analysis
- Whole-body biodistribution.
- Target-site residence time and retention kinetics.
- Blood pharmacokinetics.
- Ex vivo biodistribution.
- Direct quantitative comparison of the free peptide and the peptide loaded in the delivery system.
Outcome
The study provides a comprehensive quantitative assessment of the peptide's in vivo behavior, demonstrating whether the delivery system prolongs target-site residence time, enhances local therapeutic exposure and reduces systemic distribution compared with the free peptide. These data provide robust evidence to support formulation optimization and progression to the next stage of preclinical development.
Results are typically delivered within 2 months, depending on study design and scope.
Ready to start your molecular PET imaging study?
Schedule a technical consultation with the MIBIOTRACE team.